Beigene

Beigene Book Value per Share

The Book Value per Share of Beigene (6160.HK) as of Oct 29, 2026 is 24.96 USD. In the previous year, Book Value per Share was 19.09 USD — a change of 30.75% (higher).

Book Value per Share

24.96USD

YoY

30.75%

Last updated:

Book Value per Share of Beigene is 2025 24.96 USD. Book Value per Share of Beigene was 2024 19.09 USD. It decreases by 30.75% higher compared to the previous year.

The Beigene Book Value per Share history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Book Value per Share
Date
Book Value per Share
Jan 1, 2018
10.05 USD
Jan 1, 2019
5.61 USD
Jan 1, 2020
3.27 USD
Jan 1, 2021
35.77 USD
Jan 1, 2022
25.12 USD
Jan 1, 2023
20.27 USD
Jan 1, 2024
19.09 USD
Jan 1, 2025
24.96 USD
The Beigene Book Value per Share history
YEARBook Value per ShareYoY
24.96USD+30.75%
19.09USD-5.80%
20.27USD-19.30%
25.12USD-29.79%
35.77USD+994.07%
3.27USD-41.68%
5.61USD-44.21%
10.05USD+156.29%
3.92USD+93.88%
2.02USD-446.79%
-0.58USD-494.93%
0.15USD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Beigene Stock analysis

What does Beigene do? Beigene Ltd is a Chinese biotech company that is active in cancer research. It was founded in 2010 by experienced biotech manager John Oyler. The company is now listed on NASDAQ and also has a presence in the United States. Beigene's business model is to develop and distribute innovative cancer treatments. The company utilizes its extensive expertise in molecular and cellular biology as well as clinical development. The goal is to develop therapies that specifically target tumor cells while sparing healthy tissue. This is intended to improve patient survival rates and quality of life. Beigene specializes in the development of cancer treatments, particularly immunotherapies and precision medicine. The latter utilizes targeted attacks against tumor cells at the molecular level to achieve the most focused and effective treatment possible. The company focuses primarily on rare tumor types for which there are currently few or no effective therapies. Beigene is divided into several divisions that focus on different treatment approaches. One important division is immunotherapies, which activate the patient's own immune system against the tumor. Beigene develops antibodies, for example, that recognize and attack specific tumor cells. CAR-T cell therapy is also part of the company's portfolio. In this approach, the patient's T cells are harvested, genetically modified, and multiplied in the laboratory. These T cells are then reintroduced into the patient's body, where they target the tumor specifically. Another division of Beigene is the so-called small molecule drugs. These are chemical compounds that are introduced into the body and specifically attack tumor cells. Beigene develops inhibitors, for example, that inhibit specific enzymes and thus suppress the growth of cancer cells. Beigene has been particularly successful with its drug Zanubrutinib, which is used to treat lymphomas. The drug has achieved excellent results in clinical trials and has already been approved in several countries. Overall, Beigene is an innovative and promising biotech company that specializes in the development of new cancer treatments. The company has a strong expertise in molecular biology and has already achieved promising successes. With its various divisions and products, Beigene covers a wide range of treatment approaches and is likely to play an important role in the fight against cancer in the future. Beigene is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Beigene stock

Book Value per Share of Beigene is 24.96 USD in 2025.

Book Value per Share of Beigene changed from 19.09 USD to 24.96 USD, representing a 30.75% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Book Value per Share Beigene since 2006 – with annual values, charts, and detailed analysis.

Book value per share represents the net asset value of the company per outstanding share. Comparing it to the stock price helps assess whether a stock is undervalued.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Balance Sheet — Beigene

All Key Metrics — Beigene